<SEC-DOCUMENT>0001144204-15-045600.txt : 20150817
<SEC-HEADER>0001144204-15-045600.hdr.sgml : 20150817
<ACCEPTANCE-DATETIME>20150803080012
ACCESSION NUMBER:		0001144204-15-045600
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150731
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20150803
DATE AS OF CHANGE:		20150803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		151021063

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v416883_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 3pt 0 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT PURSUANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of report (Date of earliest event reported):
<B>July 31, 2015</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>ABEONA THERAPEUTICS INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 34%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>0-9314</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">(State&nbsp;or&nbsp;other&nbsp;jurisdiction&nbsp;of</FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">(Commission&nbsp;File&nbsp;Number)</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S.&nbsp;Employer&nbsp;Identification</FONT><BR>
<FONT STYLE="font-size: 10pt">No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>3333 Lee Parkway, Suite 600, Dallas, TX</U></B></FONT></TD>
    <TD STYLE="width: 50%; text-decoration: underline; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>75219</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>(214) 665-9495</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant&rsquo;s telephone number, including
area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD>Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="text-align: left; margin-top: 3pt; margin-bottom: 12pt; padding-top: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 8.01.&nbsp;&nbsp;Other Events </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 3, 2015, Abeona Therapeutics Inc.
(the &ldquo;Company&rdquo;) issued a press release announcing that the Company had closed an upsized $15.5 million direct placement
of registered common stock with institutional investors, including Soros Fund Management and Perceptive Life Science Fund, and
two members of the Board of Directors. The financing is comprised of 2.83 million shares of common stock at a price of $5.50 per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">A copy of the press release is furnished as
Exhibit 99.1 and is incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A copy of the &ldquo;Form of&rdquo; Purchase Agreement used in the
financing is furnished as Exhibit 10.1 and is incorporated by reference</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Item 9.01.&nbsp; Financial Statements and
Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;&#9;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>(d)&nbsp; Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">The Company hereby
furnishes the following exhibits:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">99.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Press release dated August 3, 2015, entitled
&ldquo;Abeona Therapeutics Announces Closing of Upsized $15.5 Million Equity Financing with Institutional Investors and Management&rdquo;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">Form of Purchase Agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Abeona Therapeutics Inc.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Stephen B. Thompson</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Stephen B. Thompson</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Vice President Finance</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: August 3, 2015</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>Exhibit Number</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">99.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Press release dated August 3, 2015, entitled
&ldquo;Abeona Therapeutics Announces Closing of Upsized $15.5 Million Equity Financing with Institutional Investors and Management&rdquo;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.1</TD><TD STYLE="text-align: justify">Form of Purchase Agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>v416883_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>EXHIBIT 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Abeona Therapeutics, Inc.<BR>
3333 Lee Parkway, Suite 600<BR>
Dallas, TX 75219<BR>
Attention: Chief Operating Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The undersigned (the &ldquo;<U>Investor</U>&rdquo;)
hereby confirms and agrees with you as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Purchase Agreement (the &ldquo;<U>Agreement</U>&rdquo;) is made as of July 27, 2015 between Abeona Therapeutics, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), and the Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Investor agrees to purchase from the Company, and the Company agrees to issue and sell to the Investor the number of shares of
common stock, par value $0.01 per share, (the &ldquo;<U>Shares</U>&rdquo;) of the Company set forth opposite the Investor&rsquo;s
name on Schedule A attached hereto for a purchase price of $5.50 per share, or the aggregate purchase price set forth on Schedule
A, subject to the terms and conditions hereof. The Shares have been registered and are offered for sale under the Securities Act
of 1933, as amended, pursuant to a registration statement on SEC Form S-3, Registration No. 333-205128, and the prospectus dated
June 19, 2015, which forms part of such registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
completion of the purchase and sale of the Shares (the &ldquo;<U>Closing</U>&rdquo;) shall occur on July 30, 2015 or at such other
time as the Company and the Investor mutually agree. At the Closing, the Investor shall deliver, or cause to be delivered, to the
Company by wire transfer funds in the full amount of the purchase price for the Shares being purchased. Upon receipt by the Company
of the full amount of the purchase price for such Shares, the Company shall deliver to the Investor, using customary book-entry
procedures, the number of Shares set forth for the Investor on Schedule A. The delivery of any and all Shares to the Investor shall
be conditioned upon receipt by the Company of funds in the full amount of the purchase price for the Shares being purchased by
the Investor as set forth on Schedule A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall be independent of any other agreement between the Company and any other purchaser of shares of common stock of
the Company, and the obligations of each party hereunder shall not be conditioned upon the completion of the sale of shares by
the Company to any other purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall terminate as of July 31, 2015 in the event that the Company has not received payment from the Investor of the full
amount of the purchase price for the Shares being purchased; <U>provided</U>, that the termination of this Agreement shall not
relieve the Investor from any liability arising out of its failure to perform its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Delaware, without giving effect
to the principles of conflicts of law. This Agreement may be executed in two or more counterparts, each of which shall constitute
an original, but all of which, when taken together, shall constitute but one instrument, and shall become effective when one or
more counterparts have been signed by each party hereto and delivered to the other party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Please confirm that the
foregoing correctly sets forth the agreement between us by signing in the space provided below for that purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">Name of Investor: ______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">By: _________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">Print Name: ___________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">Title: ________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">Address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">Tax ID No.: ___________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">Contact Name: _________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">Telephone: ____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">Name in which book-entry should be made (if</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">different):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">DWAC Instructions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">_____________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">DTC Participant Code: __________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 2in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">AGREED AND ACCEPTED:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase">ABEONA THERAPEUTICS, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">By: _________________________________<BR>
Name: Jeffrey B. Davis<BR>
Title: Chief Operating Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><U>SCHEDULE A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: bottom; width: 29%; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Name&nbsp;of&nbsp;Investor</b></font></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&nbsp;</td>
    <td style="vertical-align: bottom; width: 31%; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Number&nbsp;of&nbsp;Shares</b></font></td>
    <td style="vertical-align: top; width: 2%; text-align: center">&nbsp;</td>
    <td style="vertical-align: bottom; width: 36%; border-bottom: Black 1pt solid; text-align: center"><font style="font-size: 10pt"><b>Aggregate&nbsp;Purchase</b></font><br>
<font style="font-size: 10pt"><b>Price</b></font></td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>v416883_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in"><B>EXHIBIT 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<IMG SRC="tex99-1logo.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>Abeona Therapeutics
Announces Closing of Upsized $15.5 Million Equity Financing with Institutional Investors and Management</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, NY, August 3, 2015 &ndash; Abeona Therapeutics, Inc. (Nasdaq:
ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening
rare diseases,<FONT STYLE="background-color: white"> today announced it had closed an upsized $15.5 million direct placement of
registered common stock with institutional investors, including Soros Fund Management and Perceptive Life Science Fund, and two
members of the Board of Directors. The financing is comprised of 2.83 million shares of common stock at a price of $5.50 per share.
Abeona Therapeutics plans to use the proceeds of the financing for the development of its proprietary rare disease programs, working
capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;We remain encouraged by strong institutional investor interest
in our rare disease portfolio,&rdquo; stated Steven H. Rouhandeh, Executive Chairman. &ldquo;This transaction supports our strategy
of building a premier cell and gene therapy company focusing on rare diseases.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Very recently Abeona Therapeutics announced
it licensed intellectual propriety around use of the CRISPR-Cas9 gene-editing platform for use in rare blood disorders from the
laboratory of Dr. Jakub Tolar, M.D., Ph.D., at the University of Minnesota. Abeona&rsquo;s first indication utilizes the CRISPR-Cas9
platform delivered by AAV for Fanconi anemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&ldquo;In addition to advancements in our rare-disease plasma protein
programs, we have initiated production of clinical material for our two lead gene therapies for the treatment of Sanfilippo syndromes.,&rdquo;
stated Tim Miller, Ph.D, President and CEO. &ldquo;We anticipate enrolling patients in clinical trials in the fourth quarter of
this year, and demonstrating progress in our juvenile Batten disease and Fanconi anemia programs with commencement of IND enabling
studies.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">The securities described above are being offered pursuant to a
registration statement (File No. 333-205128) which became effective on July 23, 2015. When filed with the Securities and Exchange
Commission, copies of the final prospectus for the offering can be obtained at the SEC's website at <U>http://www.sec.gov</U>.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described
herein. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which
such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of
any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>About Abeona: </B>Abeona Therapeutics Inc. develops and delivers
gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AA9
NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA)
in collaboration with patient advocate groups, researchers and clinicians, anticipated to commence clinical trials in 2015. We
are also developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi
anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In
addition, we are also developing rare plasma protein therapies including SDF Alpha&trade; (alpha-1 protease inhibitor) for inherited
COPD using our proprietary SDF&trade; (Salt Diafiltration) ethanol-free process. For more information, visit <U>www.abeonatherapeutics.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Company and Media Contact:<BR>
Andre&rsquo;a Lucca<BR>
Director of Communications<BR>
Abeona Therapeutics, Inc.<BR>
+1 (212)-786-6208</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><U>alucca@abeonatherapeutics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: #444444">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><I>This press release contains certain statements
that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and
uncertainties. These statements include, without limitation, our plans for the use of proceeds of the financing, our plans to begin
enrolling patients in clinical trials for the treatment of Sanfilippo syndrome, development and internationalization of other clinical
programs, management plans for the Company, the anticipated closing of the transaction, and general business outlook. These statements
are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio,
our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies;
the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic
conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports
filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to
the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the
date of this release, whether as a result of new information, future developments or otherwise.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tex99-1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tex99-1logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ @P$\ P$1  (1 0,1 ?_$ -   0 !! (# 0
M       (!@<)"@0% 0(#"P$!  (" P$!              4'! 8" P@!"1
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M ;GG6E[0\PRT7?,+1&,,+Y;EF,PVW#TMDW5@I/(\@@"<NTS*QC8EL[@)1TX
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MY3OG)I>)<,,</RX_?3-W!\NKJ58*%N + LS7M8"O:.[5/>"E"INK9WF[]%R
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M,8P^+<O,R\_)?,SI'ERI&NSL;L2?:3_R'8=*]CXF)BX.,F)AQI%BQK9546
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M*V@'KQK',W<@^73:LF+9=X\=+& B+9JU2.NX75./@1)%$@F,/X &J&56=PB
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M;W7[I6(&,10H^(\PY%R*X9M$"!'QC.J2ZJT#'IHE $4FR=PDV:29  "@1,0
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M*I)+I*(+IIK(K)G2615(51)5)0HD4343. D.F<@B @(" @/ =00)!N.A%31
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M8ART8MU7SQ1)JT(JNH "HH8I"AXB/#61RS;\K=>,Y^VX2ALR?%D1 2%!9E(
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M8A@$IBF #%,4P<#%,4>(" @/B&G:G?H:%*4A2E*4"E* %*4H !2E . %* <
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MW$EY!9Q$.90IS"F!U%"]O'\G"]??<)1#)D9!'I(9ACK(J9&IT674H%ULX74
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5E-*4TI32E-*4TI32E-*4TI32E?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
